Zhou Yu-Peng, Wilks Moses Q, Dhaynaut Maeva, Guehl Nicolas J, Vesper Danielle R, Moon Sung-Hyun, Rice Peter A, El Fakhri Georges, Normandin Marc D, Brugarolas Pedro
Department of Radiology, Massachusetts General Hospital and Harvard Medical School, 55 Fruit St, Bulfinch 051, Boston, MA, 02114, USA.
Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT, 06520, USA.
EJNMMI Res. 2024 Apr 29;14(1):43. doi: 10.1186/s13550-024-01092-8.
4-Aminopyridine (4AP) is a medication for the symptomatic treatment of multiple sclerosis. Several 4AP-based PET tracers have been developed for imaging demyelination. In preclinical studies, [C]3MeO4AP has shown promise due to its high brain permeability, high metabolic stability, high plasma availability, and high in vivo binding affinity. To prepare for the translation to human studies, we developed a cGMP-compatible automated radiosynthesis protocol and evaluated the whole-body biodistribution and radiation dosimetry of [C]3MeO4AP in non-human primates (NHPs).
Automated radiosynthesis was carried out using a GE TRACERlab FX-C Pro synthesis module. One male and one female adult rhesus macaques were used in the study. A high-resolution CT from cranial vertex to knee was acquired. PET data were collected using a dynamic acquisition protocol with four bed positions and 13 passes over a total scan time of ~ 150 min. Based on the CT and PET images, volumes of interest (VOIs) were manually drawn for selected organs. Non-decay corrected time-activity curves (TACs) were extracted for each VOI. Radiation dosimetry and effective dose were calculated from the integrated TACs using OLINDA software.
Fully automated radiosynthesis of [C]3MeO4AP was achieved with 7.3 ± 1.2% (n = 4) of non-decay corrected radiochemical yield within 38 min of synthesis and purification time. [C]3MeO4AP distributed quickly throughout the body and into the brain. The organs with highest dose were the kidneys. The average effective dose of [C]3MeO4AP was 4.0 ± 0.6 μSv/MBq. No significant changes in vital signs were observed during the scan.
A cGMP-compatible automated radiosynthesis of [C]3MeO4AP was developed. The whole-body biodistribution and radiation dosimetry of [C]3MeO4AP was successfully evaluated in NHPs. [C]3MeO4AP shows lower average effective dose than [F]3F4AP and similar average effective dose as other carbon-11 tracers.
4-氨基吡啶(4AP)是一种用于多发性硬化症症状治疗的药物。已经开发了几种基于4AP的PET示踪剂用于脱髓鞘成像。在临床前研究中,[C]3MeO4AP因其高脑通透性、高代谢稳定性、高血浆可用性和高体内结合亲和力而显示出前景。为了准备向人体研究转化,我们开发了一种符合cGMP的自动化放射性合成方案,并评估了[C]3MeO4AP在非人灵长类动物(NHP)中的全身生物分布和辐射剂量学。
使用GE TRACERlab FX-C Pro合成模块进行自动化放射性合成。研究中使用了一只成年雄性和一只成年雌性恒河猴。采集了从颅顶到膝盖的高分辨率CT。使用动态采集方案收集PET数据,有四个床位位置,共扫描13次,总扫描时间约为150分钟。根据CT和PET图像,为选定器官手动绘制感兴趣区(VOI)。为每个VOI提取未衰变校正的时间-活度曲线(TAC)。使用OLINDA软件从积分TAC计算辐射剂量学和有效剂量。
在38分钟的合成和纯化时间内,实现了[C]3MeO4AP的全自动放射性合成,未衰变校正的放射化学产率为7.3±1.2%(n = 4)。[C]3MeO4AP迅速分布到全身并进入大脑。接受剂量最高的器官是肾脏。[C]3MeO4AP的平均有效剂量为4.0±0.6 μSv/MBq。扫描期间未观察到生命体征有显著变化。
开发了一种符合cGMP的[C]3MeO4AP自动化放射性合成方法。在NHP中成功评估了[C]3MeO4AP的全身生物分布和辐射剂量学。[C]3MeO4AP的平均有效剂量低于[F]3F4AP,与其他碳-11示踪剂的平均有效剂量相似。